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 Abstract 
Venous thromboembolism is a possible fatal complication after pelvic surgery. There is a lack 
of trials assessing the effect of prophylactic measures in urology. The aim of the study was to 
evaluate the practice of thrombosis prophylaxis in a Central European country. 
A questionnaire of performed radical prostatectomies, way of thrombosis prophylaxis and 
number of experienced thrombotic events was posted to all Hungarian departments of 
urology. 
With a response rate of 59% 506 radical prostatectomies were reported. Low molecular 
weight heparin was administered by 100% of the departments. Graduated support stockings 
were applied by 37% of the patients. Early mobilization was the most common way of 
mechanic prophylaxis (57%). Thrombotic events were experienced in 1.4%, 0.2% was fatal. 
The thrombosis prophylaxis of patients undergoing radical prostatectomy is not unified. Due 
to the potential mortality of thrombotic complications it should be evaluated and prophylaxis 
should be recommended in urological guidelines. 
Introduction 
Venous thromboembolism (VTE) – like deep vein thrombosis (DVT) and pulmonary 
embolism (PE) – is reported as complication after radical prostatectomy (RP) in 0.8 to 6.2% 
with the use of various prophylactic methods [1]. These thrombotic complications were the 
most common cause of death after oncological pelvic surgery according to a large population 
study with a ratio of 40% [2]. Guidelines were composed in order to prevent thrombotic 
events after surgical procedures, but these data are not supported by recent comparative 
studies concerning risk assessment and thrombosis prophylaxis of European centers 
performing radical prostatectomies [3; 4]. The role and way of the thrombosis prophylaxis is 
not included in the most important European urological guidelines [5]. A reason of this can be 
that there is still lack of randomized trials comparing the different pharmacologic 
interventions and ways of mechanic prophylaxis. The papers reporting the effects of 
thrombosis prophylaxis in urological surgery were published at least 20 years ago, and these 
publications don’t provide information on low molecular weight heparin (LMWH) 
administration [6; 7]. The cost-effectiveness of the different thromboprophylactic methods is 
also not evaluated regarding urological procedures. Prophylaxis of DVT was proven cost-
effective in terms of gained life-years according to a study of gynecologic procedures. 
External pneumatic compression appeared to be the most cost-effective strategy under the 
authors’ baseline assumptions against LMWH and unfractionated heparin [8]. 
The guideline of the American Urological Association recommends the following prophylaxis 
in urology related to laparoscopic and major open procedures after the determination of the 
individual thrombotic risk of the patient. Regarding laparoscopic procedures it is 
recommended to use pneumatic compression boots (PCB) at the time of the surgical 
intervention. In high-risk and very high risk groups (like laparoscopic and open radical 
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prostatectomy) patients may require the use of low dose unfractionated heparin (LDUH) or 
LMWH, but clear recommendation cannot be done regarding the use of pharmacological 
prophylaxis due to the lack of RCTs in this population. Given the increased risk factors within 
the patients’ population undergoing open urologic procedures, more aggressive regimens 
combining the use of PCB with pharmacologic prophylaxis may be considered [3; 9]. The 
recommendation is the following for open urological procedures: high risk patients require 
UFH 3x or LMWH 1x daily or PCB if bleeding high, in case of very high risk patients UFH 
3x and or LMWH 1x daily and PCB are recommended. In case of increased risk of bleeding 
mechanical prophylaxis is favored against pharmacologic prophylaxis [3].  
Hypercoagulable state after radical prostatectomy was proven by a recent trial which can be a 
predictor of thrombotic events [10] Since the second peak of thrombotic events is present at 
the fourth week after radical pelvic surgery it should be considered to use the prophylactic 
method till the end of the first postoperative month [2].  
The aims of the present study were to evaluate (a) the present practice of thrombosis 
prophylaxis, (b) the role of different prophylactic measures and (c) the ratio of thrombotic 
events in Hungary in comparison with international practice. Further aim was to advise 
discussion points to a guideline development work. 
Materials and methods 
A questionnaire was posted to every department of urology (n=37) having surgical activity in 
Hungary. In a covering letter the head of the division was requested to report retrospectively 
the number of the performed radical prostatectomies, the preferred approach, the surgeons’ 
experience, the length of the postoperative hospital stay, thrombotic risk assessment, the way 
and the length of different prophylactic methods and the number of experienced thrombotic 
events of the previous year. The responders were asked either to present their result by filling 
the questionnaire electronically (http://urology.deoec.hu/info.aspx?sp=10) or post the form 
back. All data was entered into a computer database and analyzed in an anonymous fashion. 
During the analysis Microsoft Office Excel statistics were used. 
The ethics committee of the Health Scientific Committee of the Ministry of Health approved 
the study protocol (case number: 24098-0/2010-1018EKU). The Hungarian Association of 
Urology morally supported the present research. 
 
Results 
Response rate, number and approach of radical prostatectomies 
A total response rate of 59% (22 departments) was achieved. Eight departments do not 
perform RP, so they were excluded from our study. The reported number of radical 
prostatectomies was 506 performed by the departments who filled the form, among these 
45.9% (212) was laparoscopic, 0.9% (4) was perineal and 53.2% (245) was retropubic RPs. 
The high volume centers (radical prostatectomies >50/year) performed 314 radical 
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prostatectomies (62.1% of all) Table 1. More than 70% of the procedures were performed by 
a single surgeon in 93% of the institutes. The average length of hospital stay was 10 days 
ranging from 8 to 16. 
Risk assessment and way of thrombosis prophylaxis 
Pharmacological thromboprophylaxis with LMWH once daily was preferred by 100% of the 
departments, but the practice was different Table 2. 80% of the patients are under LMWH 
administration from the 1
st
 day prior RP to the end of the 4
th
 postoperative week. None of the 
institutes reported the use of UFH. Graduated support stockings were applied by 37% of the 
patients. Although pneumatic compression boots were available by 29% of the institutes, they 
didn’t use them. Early mobilization was the most common way of mechanic prophylaxis. One 
low volume department reported the method of planned hemodilution during the surgical 
procedure for the purpose of thrombosis prophylaxis. 
Although dose adjustment of LMWH is performed in 93% of the departments and by 91% of 
the patients, risk assessment was reported only by 11 institutes. In the high-volume centers 
this is the task of the anesthesiologist, but in the smaller institutes it is a due of the urologist 
Table 3. 
Modification of ongoing anticoagulant treatment 
Acetylsalicylic acid drugs were stopped by 97% of the patients (487), and in 58% (287) they 
were replaced by LMWH. In case of thienopyridins these drugs were switched to LMWH in 
82% (416). Kumarins were replaced in 100%. The highest variation was experienced 
regarding the timing of modification of ongoing anticoagulant treatment of the patients. The 
responders reported stopping the therapy in the range of 10
th
 to 1
st
 day prior to surgery, and 
the drugs were re-administered in the range of 1
st
 to 30
th
 postoperative day. 
Thrombotic events 
According to the self-report of the institutes clinical thrombotic events were experienced in 
1.4% of the cases (7 patients): 4 were deep vein thrombosis (DVT) and 3 were pulmonary 
embolism (PE). Two DVT events occurred during the 4
th
 postoperative week, the others were 
experienced within two weeks after the surgical procedure. Two thrombotic events were 
reported by high  volume center (>50 RP/year) and two by low - volume department (<20 
RP/year). Six patients were under constant LMWH prophylaxis at the time of the thrombotic 
event. The start of the pharmacological prophylaxis varied from 1 day prior surgery to the 
first postoperative day. GSS was also applied in the first few postoperative days by 5 patients. 
Five patients underwent risk assessment and dose adjustment prior surgery, 3 of them were 
rated as high risk, the others as very high risk patients. One of the 7 events was fatal (0.2% 
referring to the whole study population) and this event was reported by a low volume 
department (3 weeks of LMWH + GSS).   
Limitations 
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The data entered by the responders regarding the thrombotic events were self-reported and 
couldn’t be verified. There were some centers in Hungary, who didn’t answer the 
questionnaire. 
Discussion 
The number of the reported radical prostatectomies represents the current practice in Hungary. 
The most experienced centers in the country prefer the laparoscopic approach. Since more 
than 70% of the procedures were performed by a single surgeon in 93% of the institutes thus 
we could draw the conclusion, that especially in the high volume centers the surgeons are 
experienced enough where most of the patients were treated (62%), which is the most 
important factor regarding the oncological and functional outcome independent from the 
preferred approach [11; 12]. Experienced centers can even perform RP in selected locally 
advanced cases with satisfactory results. [13]. Proper skill of the surgeon can also decrease 
blood loss during RP so the departments can better focus on thrombosis prophylaxis. 
The most common method of prevention is pharmacological prophylaxis in the studied 
Hungarian hospitals, although the timing of LMWH administration is not unified. These 
results were similar to the practice of UK centers as reported by Galvin [4]. In case of 
increased risk of bleeding the pharmacological prophylaxis should be replaced by the PCB, 
what wasn’t characteristic to the Hungarian departments. By almost 20% of the patients the 
LMWH administration was stopped before the end of the second week. According to different 
studies the risk of thrombotic events are present till at least the end of the first postoperative 
month [2; 10]. The role of different ways of mechanic prophylaxis was minor except the early 
mobilization.  The PCBs are available in almost 30% of the departments, but they do not use 
them. The reason of this is yet to be evaluated. 
The urologist determines the way and length of the thrombosis prophylaxis in 43% of the 
departments. Therefore it’s essential for the urological community to know the different 
methods, the presence of risk assessment and dose adjustment.  
The majority of the departments had stopped any other anticoagulant therapy or prophylaxis 
before surgery, and many of them replaced it with LMWH. The timing was really various as 
the results shows. The acetysalicylic acid is for prevention and not for anticoagulant therapy, 
so it is not absolutely necessary to replace [14]. Thienopyridins can lead to excessive bleeding 
during surgical procedures so it is recommended to replace it with LMWH 8 days before 
operation (lifetime of the thrombocytas is that long), and to switch back only when risk of 
bleeding is over [15]. Perioperative antiplatelet drugs may not increase the risk of on bleeding 
complications in urological surgery according to a recent meta-analysis, but still more high-
quality trials with larger samples and longer follow-ups are required. [16]. 
The ratio of the reported thrombotic events is similar to the international results [1]. The fact 
that all 7 patients were administered LMWH and 6 of them were still protected by the drug 
raises the question that is pharmacological prophylaxis alone or in combination with early 
mobilization and GSS appropriate for preventing venous thromboembolism? Should 
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urologists use PCB in every case? These questions will remain unanswered till more papers 
will be published regarding this topic. But as urologists it is essential to know the different 
prophylactic methods, and to evaluate the effectiveness of the known ones. It would be 
beneficial if the European Association of Urology (EAU) Guidelines – which is a bible for all 
European urologists – would include recommendation of thrombosis prophylaxis in urology 
like it is presented by the American Urological Association [5]. An all European study – or at 
least presented by each country – of the present practice of thrombosis prophylaxis would 
reveal the effectiveness of the different ways of prophylaxis. 
Conclusion 
The thrombosis prophylaxis of patients undergoing radical prostatectomy is not unified. Due 
to the potential mortality of thrombotic complications as urologists it is essential to know the 
different prophylactic methods, and to evaluate the effectiveness of the known ones. It would 
be beneficial that urological guidelines would include a chapter of thromboprophylaxis as 
well.  
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Table 1: Centers experience according to the performed RPs 
Number 
of 
RPs/year 
Number of 
departments 
Number of 
patients 
Number of 
retropubic 
RPs 
Number of 
perineal RPs 
Number of 
laparoscopic 
RPs 
<20 6 81 77 4 0 
20-50 4 111 104 0 7 
>50 4 314 109 0 205 
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Table 2: Administration of the different prophylactic methods  
(GSS: graduated support stockings, PCB: pneumatic compression boots) 
*availability of PCB in the institute/hospital but none of them were used 
 
  
Nr. of 
patients 
Percentage 
(%) 
Nr. of 
centers 
Percentage 
(%) 
LMWH 
start 
1 day prior RP 409 80,8 10 71,4 
on the day of RP 52 10,3 3 21,4 
1
st
 postop. day 45 8,9 1 7,1 
LMWH 
stop 
5
th
 postop. day 15 3,0 1 7,1 
10
th
 postop. day 84 16,6 1 7,1 
21
st
 postop. day 12 2,4 1 7,1 
28
th
 postop. day 395 78,1 11 78,6 
GSS 187 37,0 8 57,1 
Mobilisation on 1
st
 postop. 
day 353 69,8 8 57,1 
Mobilisation on 2
nd
 postop. 
day 131 25,9 4 28,6 
(PCB*) 196 38,7 4 28,6 
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Table 3: Ratio of dose adjustment and risk assessment 
  
Nr. of 
patients 
Percentage 
(%) 
Nr. of 
centers 
Percentage 
(%) 
Dose adjustment 461 91,1 13 92,9 
Risk assessment 381 75,3 11 78,6 
Risk 
assessment 
by 
anesthesiologist 279 55,1 4 28,6 
urologist 95 18,8 6 42,9 
together 37 7,3 2 14,3 
not reported 95 18,8 2 14,3 
 
 
